The clinical applicability of G-quadruplexes (G4s) as anticancer drugs is currently being
evaluated. Several G4 ligands and aptamers are undergoing clinical trials following the …

Cancer is one of the leading causes of death worldwide. Conventional therapies, including
surgery, radiation, and chemotherapy have achieved increased survival rates for many types …

Abstract Development of proteolysis targeting chimeras (PROTACs) is emerging as a
promising strategy for targeted protein degradation. However, the drug development using …

Aptamers are single-stranded nucleic acid molecules that bind to and inhibit proteins and
are commonly produced by systematic evolution of ligands by exponential enrichment …

Metastasis has intrigued researchers for more than 100 years. Despite the development of
technologies and therapeutic strategies, metastasis is still the major cause of cancer-related …

Nucleolin or C23, is one of the most abundant non-ribosomal phosphoproteins of nucleolus.
However, in several cancers, nucleolin is highly expressed both intracellularly and on the …

Chemodynamic therapy (CDT) has demonstrated new possibilities for selective and logical
cancer intervention by specific manipulation of dysregulated tumorous free radical …

Background AS1411 is a 26-mer G-rich DNA oligonucleotide that forms a variety of G-
quadruplex structures. It was identified based on its cancer-selective antiproliferative activity …

Nucleic acids are a promising type of therapeutic for the treatment of a wide range of
conditions, including cancer, but they also pose many delivery challenges. For efficient and …

Paclitaxel (PTX) is among the most commonly used first-line drugs for cancer chemotherapy.
However, its poor water solubility and indiscriminate distribution in normal tissues remain …